#706 1983 · U.S. Congress (Rep. Henry Waxman) / Abbey Meyers · Pharmaceuticals / rare disease drug development
Congress fixed rare-disease drugs' incentive problem by granting exclusivity to drugs no patent could ever cover
the problem
Patent protection couldn't incentivize treatments built on already-unpatentable, decades-old compounds
background
By the early 1980s, patients with rare diseases faced what came to be called "pharmaceutical orphans" — conditions affecting too few people for a company to expect to recoup the cost of clinical trials and regulatory approval, even when a promising treatment already existed in some form. Abbey Meyers, whose son had Tourette syndrome, discovered this firsthand when a drug that had been helping him became unavailable because the manufacturer had no financial reason to keep pursuing FDA approval for a market that small.
Meyers and a coalition of rare-disease patient advocates began lobbying Congress, and actor Jack Klugman, star of the television show Quincy, M.E., testified on the issue after featuring a rare-disease storyline on his show. But simply strengthening patent protection, the industry's usual incentive, couldn't fix the underlying problem: many of the most promising rare-disease treatments were built on decades-old compounds, naturally occurring substances, or drugs that had never been patentable in the first place, leaving nothing for a stronger patent to protect.
what everyone would do
Rely on ordinary patent protection to motivate pharmaceutical companies to develop rare-disease treatments the same way it motivated everything else in the industry — the standard incentive mechanism, and one that simply couldn't work for the many rare-disease treatments built on decades-old, already-generic, or naturally occurring compounds that had never been patentable to begin with.
what they saw
The problem wasn't that rare-disease markets were small — small markets can still be profitable if a company can be confident of capturing them exclusively. The real problem was narrower and more specific: many of the most promising rare-disease treatments used compounds that were already off-patent or had never been patentable at all, so there was no patent left to grant exclusivity through, no matter how the law was tweaked. Henry Waxman's bill solved this by decoupling exclusivity from patents entirely — granting seven years of market exclusivity as a direct reward for winning regulatory approval to treat a specific rare disease, regardless of whether the underlying drug itself could be patented.
the move
Representative Henry Waxman's bill, signed into law by President Reagan on January 4, 1983 as the Orphan Drug Act, granted seven years of market exclusivity to any company that won FDA approval to treat a designated rare disease — regardless of whether the drug itself was patentable — alongside federal grants for clinical trials and a 50 percent tax credit on testing costs.
why it works
By tying exclusivity to the act of gaining FDA approval for a specific rare-disease indication rather than to patent ownership, the law created a genuinely new incentive where none had existed — a company could invest in the clinical trials needed to prove an old, unpatentable compound worked against a rare disease, knowing that even without a patent, no competitor could sell an equivalent drug for that same use for seven years after approval. Because the exclusivity attached to the approval itself, it worked exactly as well for a decades-old, off-patent molecule as for a brand-new patentable one, closing the specific gap ordinary patent law had left open.
the payoff
Because the exclusivity was tied to regulatory approval rather than patent ownership, it rewarded a company for proving an old, unpatentable compound worked against a rare disease just as effectively as it would have rewarded a brand-new patentable one. Five months after the law passed, Meyers and her fellow advocates founded the National Organization for Rare Disorders (NORD), with Meyers as its first president, to keep pressing for further reforms.
where it breaks
It only rewards genuine investment in developing and proving a treatment — a company that already sells a drug for a common condition can seek orphan designation for a narrower rare-disease use of the same drug and capture years of exclusivity on relatively little incremental work, a criticism that has followed the Act for decades as companies found ways to orphan-designate drugs already profitable elsewhere. And exclusivity granted through regulatory approval rather than patent examination sidesteps the patent system's own novelty and inventiveness requirements, which is precisely the flexibility that makes the mechanism powerful and also the reason it's been contested as a loophole rather than purely a cure.
what came after
The Orphan Drug Act's patent-independent exclusivity model has since been adapted by other countries' drug regulators and extended in the U.S. to related incentive programs, and it remains credited with transforming rare-disease drug development from a market nobody would enter into a real, if still contested, area of pharmaceutical investment; the same design has also drawn decades of criticism from those who argue companies have learned to use narrow orphan designations to extend exclusivity on drugs that are already profitable in broader markets.
references
- [1]Orphans in the Market: The History of Orphan Drug PolicySocial History of Medicine, via PubMed Central, 2019pmc.ncbi.nlm.nih.gov
- [2]Designating an Orphan Product: Drugs and Biological ProductsU.S. Food and Drug Administration, 2024fda.gov